- Home
- Publications
- Publication Search
- Publication Details
Title
Updates on breast biomarkers
Authors
Keywords
-
Journal
VIRCHOWS ARCHIV
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2022-01-14
DOI
10.1007/s00428-022-03267-x
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- 70-gene signature as an aid for treatment decisions in early breast cancer: updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by age
- (2021) Martine Piccart et al. LANCET ONCOLOGY
- Retrospective observational study of HER2 immunohistochemistry in borderline breast cancer patients undergoing neoadjuvant therapy, with an emphasis on Group 2 (HER2/CEP17 ratio ≥2.0, HER2 copy number
- (2021) Emad A. Rakha et al. BRITISH JOURNAL OF CANCER
- Phenotypic discordance between primary and metastatic breast cancer in the large-scale real-life multicenter French ESME cohort
- (2021) Thomas Grinda et al. npj Breast Cancer
- HER2 Testing
- (2021) Erin V. Grimm et al. APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY
- Letter to the Editor for ‘Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study’
- (2021) N. Harbeck et al. ANNALS OF ONCOLOGY
- Estrogen and Progesterone Receptor Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Guideline Update
- (2020) Kimberly H. Allison et al. ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE
- Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline Update
- (2020) Kimberly H. Allison et al. JOURNAL OF CLINICAL ONCOLOGY
- Prognostic Value of EndoPredict in Women with Hormone Receptor–Positive, HER2-Negative Invasive Lobular Breast Cancer
- (2020) Ivana Sestak et al. CLINICAL CANCER RESEARCH
- Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial
- (2020) Javier Cortes et al. LANCET
- High Frequency of ERBB2 Activating Mutations in Invasive Lobular Breast Carcinoma with Pleomorphic Features
- (2019) Juan Rosa-Rosa et al. Cancers
- Impact of the 2018 ASCO/CAP HER2 Guideline Focused Update
- (2019) Adlin M Gordian-Arroyo et al. AMERICAN JOURNAL OF CLINICAL PATHOLOGY
- Randomized Placebo Controlled Trial of Low-Dose Tamoxifen to Prevent Local and Contralateral Recurrence in Breast Intraepithelial Neoplasia
- (2019) Andrea DeCensi et al. JOURNAL OF CLINICAL ONCOLOGY
- Alpelisib for PIK3CA-Mutated, Hormone Receptor–Positive Advanced Breast Cancer
- (2019) Fabrice André et al. NEW ENGLAND JOURNAL OF MEDICINE
- ASCO/CAP 2018 breast cancer HER2 testing guidelines: summary of pertinent recommendations for practice in Australia
- (2019) Gelareh Farshid et al. PATHOLOGY
- Tamoxifen therapy improves overall survival in luminal A subtype of ductal carcinoma in situ: a study based on nationwide Korean Breast Cancer Registry database
- (2018) Ki-Tae Hwang et al. BREAST CANCER RESEARCH AND TREATMENT
- Borderline ER-Positive Primary Breast Cancer Gains No Significant Survival Benefit From Endocrine Therapy: A Systematic Review and Meta-Analysis
- (2018) Tong Chen et al. Clinical Breast Cancer
- Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update
- (2018) Antonio C. Wolff et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children
- (2018) Alexander Drilon et al. NEW ENGLAND JOURNAL OF MEDICINE
- HER2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update Summary
- (2018) Antonio C. Wolff et al. Journal of Oncology Practice
- Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation
- (2018) Jennifer K. Litton et al. NEW ENGLAND JOURNAL OF MEDICINE
- Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer
- (2018) Peter Schmid et al. NEW ENGLAND JOURNAL OF MEDICINE
- Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer
- (2018) Gunter von Minckwitz et al. NEW ENGLAND JOURNAL OF MEDICINE
- Long-Term Prognostic Risk After Neoadjuvant Chemotherapy Associated With Residual Cancer Burden and Breast Cancer Subtype
- (2017) W. Fraser Symmans et al. JOURNAL OF CLINICAL ONCOLOGY
- Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
- (2017) Mark Robson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy
- (2017) Norikazu Masuda et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
- (2017) Dung T. Le et al. SCIENCE
- Assessing the New American Society of Clinical Oncology/College of American Pathologists Guidelines forHER2Testing by Fluorescence In Situ Hybridization: Experience of an Academic Consultation Practice
- (2016) Michael F. Press et al. ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE
- NonamplificationERBB2genomic alterations in 5605 cases of recurrent and metastatic breast cancer: An emerging opportunity for anti-HER2 targeted therapies
- (2016) Jeffrey S. Ross et al. CANCER
- HER2Gene Amplification Testing by Fluorescent In Situ Hybridization (FISH): Comparison of the ASCO-College of American Pathologists Guidelines With FISH Scores Used for Enrollment in Breast Cancer International Research Group Clinical Trials
- (2016) Michael F. Press et al. JOURNAL OF CLINICAL ONCOLOGY
- ‘Non-classical’ HER2 FISH results in breast cancer: a multi-institutional study
- (2016) Morgan Ballard et al. MODERN PATHOLOGY
- Predictive and prognostic cancer biomarkers revisited
- (2015) Kenneth PH Pritzker EXPERT REVIEW OF MOLECULAR DIAGNOSTICS
- Impact of updated HER2 testing guidelines in breast cancer—re-evaluation of HERA trial fluorescence in situ hybridization data
- (2015) Oliver C Stoss et al. MODERN PATHOLOGY
- Low ER+ Breast Cancer
- (2014) Nika C. Gloyeske et al. AMERICAN JOURNAL OF CLINICAL PATHOLOGY
- Which threshold for ER positivity? a retrospective study based on 9639 patients
- (2014) M. Yi et al. ANNALS OF ONCOLOGY
- Proportion of estrogen or progesterone receptor expressing cells in breast cancers and response to endocrine therapy
- (2014) Naoko Honma et al. BREAST
- Updated UK Recommendations for HER2 assessment in breast cancer
- (2014) Emad A Rakha et al. JOURNAL OF CLINICAL PATHOLOGY
- Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
- (2014) Patricia Cortazar et al. LANCET
- HER2 Testing of Multifocal Invasive Breast Carcinoma
- (2013) Gillian C. Bethune et al. AMERICAN JOURNAL OF CLINICAL PATHOLOGY
- Survival Outcomes in Breast Cancer Patients With Low Estrogen/Progesterone Receptor Expression
- (2013) Alessandra Balduzzi et al. Clinical Breast Cancer
- Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update
- (2013) Antonio C. Wolff et al. JOURNAL OF CLINICAL ONCOLOGY
- HER2 in situ hybridization in breast cancer: clinical implications of polysomy 17 and genetic heterogeneity
- (2013) Wedad M Hanna et al. MODERN PATHOLOGY
- Effect of ASCO/CAP Guidelines for Determining ER Status on Molecular Subtype
- (2012) Brenda Deyarmin et al. ANNALS OF SURGICAL ONCOLOGY
- Estrogen Receptor (ER) mRNA and ER-Related Gene Expression in Breast Cancers That Are 1% to 10% ER-Positive by Immunohistochemistry
- (2012) Takayuki Iwamoto et al. JOURNAL OF CLINICAL ONCOLOGY
- Adjuvant Tamoxifen Reduces Subsequent Breast Cancer in Women With Estrogen Receptor–Positive Ductal Carcinoma in Situ: A Study Based on NSABP Protocol B-24
- (2012) D. Craig Allred et al. JOURNAL OF CLINICAL ONCOLOGY
- Activating HER2 Mutations in HER2 Gene Amplification Negative Breast Cancer
- (2012) Ron Bose et al. Cancer Discovery
- Frequency of HER2 Heterogeneity by Fluorescence In Situ Hybridization According to CAP Expert Panel Recommendations
- (2011) Kimberly H. Allison et al. AMERICAN JOURNAL OF CLINICAL PATHOLOGY
- Impact of low estrogen/progesterone receptor expression on survival outcomes in breast cancers previously classified as triple negative breast cancers
- (2011) Kanwal P. S. Raghav et al. CANCER
- Determining TrueHER2Gene Status in Breast Cancers With Polysomy by Using Alternative Chromosome 17 Reference Genes: Implications for Anti-HER2Targeted Therapy
- (2011) Chun Hing Tse et al. JOURNAL OF CLINICAL ONCOLOGY
- American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer
- (2010) M. Elizabeth H. Hammond et al. JOURNAL OF CLINICAL ONCOLOGY
- Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ: long-term results from the UK/ANZ DCIS trial
- (2010) Jack Cuzick et al. LANCET ONCOLOGY
- Absence of chromosome 17 polysomy in breast cancer: analysis by CEP17 chromogenic in situ hybridization and multiplex ligation-dependent probe amplification
- (2009) Cathy B. Moelans et al. BREAST CANCER RESEARCH AND TREATMENT
- Does chromosome 17 centromere copy number predict polysomy in breast cancer? A fluorescencein situhybridization and microarray-based CGH analysis
- (2009) Caterina Marchiò et al. JOURNAL OF PATHOLOGY
- Clinical validation of an array CGH test for HER2 status in breast cancer reveals that polysomy 17 is a rare event
- (2009) I-Tien Yeh et al. MODERN PATHOLOGY
- HER2 testing in the UK: further update to recommendations
- (2008) R A Walker et al. JOURNAL OF CLINICAL PATHOLOGY
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started